Hi everyone, Jules here.
I have been sent some information regarding our fears that mums trial will not go ahead due to costs (using nivolumab and ipilimumab.
But it looks like this may not be the case - yhought i should copy what i have been sent here as a separate post in case someone else is in the same boat.
Found these items online which seem to suggest that the NHS consider the duo cost-effective, so fingers crossed for positive news in May.
ICER for nivolumab plus ipilimumab compared to pembrolizumab is likely to be less than £30,000 per QALY gained in the mixed population of BRAF mutation-positive and mutation-negative advanced melanoma when the patient access scheme prices were used in the model. It therefore considered that nivolumab plus ipilimumab could be considered a cost-effective use of NHS resources.
The incremental cost-effectiveness ratio (ICER) is a statistic used in cost-effectiveness analysis to summarise the cost-effectiveness of a health care intervention. It is defined by the difference in cost between two possible interventions, divided by the difference in their effect.